Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | RLY-5836 |
Trade Name | |
Synonyms | RLY 5836|RLY5836 |
Drug Descriptions |
RLY-5836 is a mutant-selective PIK3CA inhibitor, which potentially induces apoptosis and inhibits growth of tumor cells expressing mutant PIK3CA (Cancer Res (2024) 84 (9_Supplement): PO3-20-04, NCI Drug Dictionary). |
DrugClasses | PIK3CA inhibitor 26 |
CAS Registry Number | NA |
NCIT ID | C199577 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Abemaciclib + Fulvestrant + RLY-5836 | Abemaciclib Fulvestrant RLY-5836 | 0 | 1 |
Fulvestrant + Palbociclib + RLY-5836 | Fulvestrant Palbociclib RLY-5836 | 0 | 1 |
Fulvestrant + Ribociclib + RLY-5836 | Fulvestrant RLY-5836 Ribociclib | 0 | 1 |
Fulvestrant + RLY-5836 | Fulvestrant RLY-5836 | 0 | 1 |
RLY-5836 | RLY-5836 | 0 | 1 |